Clinical Development Failure Risk: The company's lead product candidates may not succeed in clinical trials, failing to demonstrate efficacy or safety, which could lead to significant delays, increased costs, or discontinuation of development.

Regulatory Approval Uncertainty Risk: Even if clinical trials are successful, obtaining necessary regulatory approvals from health authorities like the FDA is a complex and uncertain process, with no guarantee that OKYO's product candidates will receive the required marketing authorizations.

Funding and Capital Availability Risk: Developing pharmaceutical products is capital-intensive, and OKYO may need to raise substantial additional capital in the future, which might not be available on favorable terms or at all, potentially leading to delays or cessation of programs.